Physician profile
Gool Gupta
NPI 1376507251
$422.70
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $83.46 · 2021: $98.31 · 2022: $123.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $99.26 | 2021-2022 | |
| Janssen Biotech, INC. | $71.59 | 2019 | |
| Novo Nordisk INC | $70.04 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $38.62 | 2021-2022 | |
| Angiodynamics, INC. | $23.89 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $19.82 | 2020 | |
| Merck Sharp & Dohme LLC | $16.71 | 2022 | |
| Philips North America LLC | $15.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.75 | 2022 | |
| Horizon Therapeutics Plc | $13.89 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $13.82 | 2022 | |
| Pfizer INC. | $13.34 | 2021 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gool Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.